EOD Primary Tumor

This input is used for staging

Notes

**Note 1:** Melanoma in situ is also called primary acquired melanosis. **Note 2:** The EOD Primary Tumor collapses the clinical and pathological information. Pathological evidence takes priority over clinical evidence, unless the clinical evidence was clearly greater or the patient had neoadjuvant treatment. **Note 3:** Nodular or well-defined conjunctival melanomas are clinically categorized according to the regional location of their posterior and anterior margins (i.e., cornea, limbus, bulbar conjunctiva, fornix, palpebral conjunctiva, plica, caruncle, or eyelid skin) and by their circumferential extent, in clock minutes, in each of these regions. A “quadrant” comprises 15 clock minutes regardless of the meridian locations of the lateral margins.

Default

999

NAACCR Item

NAACCR #772
Code Description SS2018 T
000 In situ, intraepithelial, noninvasive Melanoma confined to the conjunctival epithelium (in situ) IS
100 CLINICAL assessment only Less than or equal to one quadrant involved PATHOLOGICAL assessment only Bulbar conjunctiva tumor with invasion of substantia propria, less than or equal to 2.0 mm in thickness L
110 CLINICAL assessment only Greater than 1 quadrant and less than or equal to 2 quadrants involved PATHOLOGICAL assessment only Bulbar conjunctiva tumor with invasion of substantia propria, greater than 2.0 mm in thickness L
120 CLINICAL assessment only Greater than 2 quadrants and less than or equal to 3 quadrants involved L
130 CLINICAL assessment only Greater than 3 quadrants involved L
150 Tumor(s) of bulbar conjunctiva, NOS Localized, NOS L
200 CLINICAL assessment only Noncaruncular tumor - AND less than or equal to 1 quadrant of nonbulbar conjunctiva involved PATHOLOGICAL assessment only Nonbulbar conjunctiva tumor with invasion of substantia propria, less than or equal to 2.0 mm in thickness - WITH or WITHOUT involvement of caruncle L
250 CLINICAL assessment only Noncaruncular tumor - AND greater than 1 quadrant of nonbulbar conjunctiva (forniceal, palpebral, tarsal) involved PATHOLOGICAL assessment only Nonbulbar conjunctiva tumor with invasion of substantia propria, greater than 2.0 mm in thickness - WITH or WITHOUT involvement of caruncle L
300 CLINICAL assessment only Caruncular tumor - AND less than or equal to 1 quadrant of nonbulbar conjunctiva (forniceal, palpebral, tarsal) involved L
350 CLINICAL assessment only Caruncular tumor - AND greater than 1 quadrant of nonbulbar conjunctiva (forniceal, palpebral, tarsal) involved L
400 CLINICAL assessment only Tumor(s) of nonbulbar (forniceal, palpebral, tarsal) involved, NOS WITH corneal extension PATHOLOGICAL assessment only Involvement of caruncle WITH extension to cornea L
450 Invasion of globe RE
500 Invasion of eyelid RE
550 Invasion of orbit RE
600 Invasion of - Lacrimal sac - Nasolacrimal duct - Paranasal sinuses RE
650 Invasion of sinus, NOS D
700 Local invasion, NOS RE
750 Invasion of the central nervous system Further contiguous extension RE
800 No evidence of primary tumor U
999 Unknown; extension note stated Primary tumor cannot be assessed Not documented in patient record Death Certificate Only U
(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998 (2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001. (3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL) (4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 3-30 (5) Coupland, S.E., Finger, P.T., et al. **Conjunctival Melanoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 795-803